Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XENLETA (lefamulin) is first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics team. It is designed to inhibit the synthesis of bacterial protein, which is required...
Product Name : Xenleta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 28, 2022
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Xenleta (lefamulin) is a novel, first-in-class, IV and oral pleuromutilin antimicrobial agent that has been demonstrated to be highly potent against S. aureus, including MRSA and strains obtained from patients with CF.
Product Name : Xenleta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 08, 2022
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XENLETA has the potential to provide a well-tolerated oral and intravenous anti-MRSA treatment option with a novel mechanism for this difficult to treat patient population. We look forward to sharing the results of this study with the medical community.
Product Name : Xenleta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 04, 2022
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PRX004
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Novo Nordisk
Deal Size : $1,200.0 million
Deal Type : Acquisition
Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena’s ATTR Amyloidosis Programme
Details : PRX004 is a phase 2 ready anti-amyloid immunotherapy designed to deplete the amyloid deposits that are associated with the disease pathology of ATTR amyloidosis.
Product Name : PRX004
Product Type : Antibody
Upfront Cash : $100.0 million
December 07, 2021
Lead Product(s) : PRX004
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Novo Nordisk
Deal Size : $1,200.0 million
Deal Type : Acquisition
Lead Product(s) : PRX004
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021
Details : In this Phase 1 study, PRX004 was found to be generally safe and well tolerated across all dose levels. Positive clinical findings suggest PRX004’s depleter mechanism of action can result in benefits in both neuropathy and cardiac function.
Product Name : PRX004
Product Type : Antibody
Upfront Cash : Inapplicable
April 18, 2021
Lead Product(s) : PRX004
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PRX004
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Prothena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004
Details : In the first report of clinical results with this depleter mechanism of action, PRX004 showed favorable results as demonstrated by slowing of neuropathy progression for all 7 evaluable patients at 9 months.
Product Name : PRX004
Product Type : Antibody
Upfront Cash : Inapplicable
September 12, 2020
Lead Product(s) : PRX004
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Inzomelid
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Inzomelid is a potent, selective, orally-available, brain-penetrant NLRP3 inflammasome inhibitor intended for treatment of debilitating inflammatory diseases.
Product Name : IZD174
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 14, 2020
Lead Product(s) : Inzomelid
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Inzomelid
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase I study demonstrated Inzomelid has an excellent safety, tolerability and pharmacokinetic profile in healthy subjects, with dose-dependent target engagement.
Product Name : IZD174
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 26, 2020
Lead Product(s) : Inzomelid
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable